


RealRate

PHARMACEUTICAL 2018











RealRate

PHARMACEUTICAL 2018

ELI LILLY & Co Rank 76 of 349



The relative strengths and weaknesses of ELI LILLY & Co are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of ELI LILLY & Co compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 274% points. The greatest weakness of ELI LILLY & Co is the variable Other Expenses, reducing the Economic Capital Ratio by 59% points.

The company's Economic Capital Ratio, given in the ranking table, is 32%, being 309% points above the market average of -278%.

Input Variable	Value in 1000 USD
Assets, Current	19,202,100
Cost of Goods Sold	0
Intangible Assets	8,399,300
Liabilities, Current	14,535,900
Liabilities, Non-Current	18,777,200
Other Assets	8,553,100
Other Compr. Net Income	174,500
Other Expenses	11,205,500
Other Liabilities	0
Other Net Income	0
Property and Equipment	8,826,500
Research and Development	5,281,800
Revenues	22,871,300
Selling, General and Administrative Expense	6,588,100

Output Variable	Value in 1000 USD
Assets	44,981,000
Liabilities	33,313,100
Expenses	23,075,400
Stockholders Equity	11,667,900
Net Income	-204,100
Comprehensive Net Income	-116,850
Economic Capital Ratio	32%

